Amnis and Gene Company Announce Agreement to Market ImageStream Technology in China
News May 09, 2008
Amnis Corporation and Gene Company, Ltd. announced the completion of an agreement under which Gene Company will sell and service the Amnis ImageStream® system in China. Effective immediately, the scientific research communities in Hong Kong, Shanghai, Beijing and Guangzhou now have access to this important cell analysis technology.
"We are extremely pleased to have begun what we expect will be a valuable partnership with Gene Company. We are looking forward to working with them to expand the commercial presence of the ImageStream in China," said David Basiji, Ph.D., Amnis' President and CEO.
"Gene Company has a strong presence in the major Chinese scientific markets and brings a distinguished history as a supplier to the partnership. We are quite confident that they will represent the ImageStream extremely well,” He added.
Dr. Cheung To, Chairman of Gene Company, added, "We envisage that distribution of the Amnis ImageStream system will remarkably empower pioneering labs with next generation microscopy and flow cytometry in a single platform to advance applications in drug discovery, molecular and cellular research and diagnostics in China. Gene Company has high confidence in Amnis and looks forward to a synergetic cooperation."
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.